Related Experiment Video
Updated: Jul 6, 2026
06:55
Assessment of Maternal Vascular Remodeling During Pregnancy in the Mouse Uterus
Published on: December 5, 2015
Maternal morbidity, mortality, and risk assessment.
1Department of Anesthesiology, Baylor College of Medicine, Faculty Center, Houston, TX 77030, USA. msuresh@bcm.tmc.edu
Anesthesiology Clinics
|March 6, 2008
Summary
Maternal deaths are rare in developed nations but exceed 0.5 million annually in developing countries. This article examines risks and prevention strategies for maternal mortality.
Area of Science:
- Obstetrics and Gynecology
- Global Health
- Public Health
Background:
- Maternal mortality rates show significant disparities between developed and developing countries.
- While rare in developed nations like the US and UK, maternal deaths remain a critical issue globally.
- Over 500,000 maternal deaths occur annually in developing regions.
Purpose of the Study:
- To assess the morbidity risks associated with leading causes of maternal death.
- To highlight effective strategies for minimizing maternal morbidity and mortality.
- To provide insights into preventing maternal deaths in high-risk regions.
Main Methods:
- Review of epidemiological data on maternal mortality and morbidity.
- Analysis of risk factors for major causes of maternal death.
- Identification and synthesis of evidence-based prevention and management strategies.
Main Results:
- Leading causes of maternal death present significant morbidity risks.
- Effective interventions exist to reduce maternal complications and fatalities.
- Disparities in healthcare access and quality contribute to higher mortality in developing countries.
Conclusions:
- Targeted strategies are crucial for reducing maternal mortality in developing countries.
- Minimizing morbidity risks is key to preventing maternal deaths.
- Global collaboration and resource allocation are essential for improving maternal health outcomes.
Related Concept Videos
01:19Mitral Valve Prolapse III: Nursing Management
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
01:28Development of the Oral Microbiota
The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...